At a Glance
- The first oral form of Wegovy is now on sale in the U.S.
- Prescription still required; telehealth partners offer quick access
- Starting price: $149 a month before insurance
- Why it matters: Patients who dislike needles get a proven GLP-1 option that matched injection results in trials
Wegovy’s new daily pill brings the same active ingredient, semaglutide, into a tablet for the first time, giving U.S. consumers another FDA-approved route for chronic weight management.
How to Get It
Doctors must write a prescription. To speed access, maker Novo Nordisk teamed up with:
- Ro
- LifeMD
- NovoCare Pharmacy
- GoodRx
- Weight Watchers Med+ program
Patients connect through those platforms, complete an evaluation, and-if eligible-receive the medication by mail.
Pricing Breakdown
| Dose | Monthly Cost (Self-Pay) |
|---|---|
| 1.5 mg | $149 |
| 4 mg | $149 until April 15, then $199 |
| 9 mg & 25 mg | $299 |
Insurance may drop the price to as low as $25 for covered users. Telehealth consultation fees are extra.
Clinical Results
Trial participants who took the pill, ate a reduced-calorie diet, and exercised lost 17% of their body weight on average, matching the performance of Wegovy injections.
Weight Watchers Chief Commercial Officer Scott Honken called oral GLP-1s “a real breakthrough” that removes “long-standing barriers like access, friction, and affordability.”
Key Takeaways
- Wegovy pill is available nationwide with a prescription
- Telehealth partnerships aim to cut wait times
- $149 monthly entry cost undercuts many branded obesity drugs
- 17% average weight loss shown when combined with diet and exercise
The launch marks the next phase in the GLP-1 weight-loss race, this time without a needle.
